Solti Breast Cancer Research Group

This study is testing a new three-drug combination for people with advanced HER2-positive breast cancer that has stopped responding to standard treatments. It combines an immunotherapy drug (atezolizumab) with two established cancer drugs (trastuzumab and vinorelbine). The goal i…

This study aims to understand why some patients respond better than others to the cancer drug trastuzumab deruxtecan. Researchers will analyze tumor and blood samples from 180 patients with metastatic cancer who have received this treatment. The goal is to find biological markers…